Similar Papers

Paper Title
Journal
Date
Author
SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.
Jihong Liu ... Li Wang
Journal of Clinical Oncology | VOL. 41
Jihong Liu, et. al.Jihong Liu ... Li Wang
01 Jun 2023
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
Xiaohua Wu ... Michelle Xia
The Lancet | VOL. 404
Xiaohua Wu, et. al.Xiaohua Wu ... Michelle Xia
01 Oct 2024
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Alain Lortholary ... Yukiharu Todo
The Lancet | VOL. 403
Alain Lortholary, et. al.Alain Lortholary ... Yukiharu Todo
01 Dec 2023
First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis
Jianying Lei ... Na Li
Value in Health | VOL. 27
Jianying Lei, et. al.Jianying Lei ... Na Li
02 Aug 2024
View more papers

More From: Gynecologic Oncology

Paper Title
Journal
Date
Author
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Aine Clements ... Angeles Alvarez Secord
Gynecologic oncology | VOL. 193
Aine Clements, et. al.Aine Clements ... Angeles Alvarez Secord
23 Jan 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
David M O'Malley ... Michele Maio
Gynecologic oncology | VOL. 193
David M O'Malley, et. al.David M O'Malley ... Michele Maio
22 Jan 2025
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
Michael D Toboni ... Nathaniel Jones
Gynecologic oncology | VOL. 193
Michael D Toboni, et. al.Michael D Toboni ... Nathaniel Jones
20 Jan 2025
Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.
M Schaafsma ... N.E Van Trommel
Gynecologic oncology | VOL. 193
M Schaafsma, et. al.M Schaafsma ... N.E Van Trommel
17 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.